Bayesian Modeling Immune Reconstitution Apply to CD34+ Selected Stem Cell Transplantation for Severe Combined Immunodeficiency.
Bayesian prediction algorithm
CD34+ selection
hematopoietic stem cell transplantation
immune reconstitution
severe combined immunodeficiency (SCID)
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
10
2021
accepted:
21
12
2021
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
5
3
2022
Statut:
epublish
Résumé
Severe combined immunodeficiencies (SCIDs) correspond to the most severe form of primary immunodeficiency. Allogeneic hematopoietic stem cell transplantation (HSCT) and gene therapy are curative treatments, depending on the donor's availability and molecular diagnostics. A partially human leukocyte antigen (HLA)-compatible donor used has been developed for this specific HSCT indication in the absence of a matched donor. However, the CD34+ selected process induces prolonged post-transplant T-cell immunodeficiency. The aim here was to investigate a modeling approach to predict the time course and the extent of CD4+ T-cell immune reconstitution after CD34+ selected transplantation. We performed a Bayesian approach based on the age-related changes in thymic output and the cell proliferation/loss model. For that purpose, we defined specific individual covariates from the data collected from 10 years of clinical practice and then evaluated the model's predicted performances and accuracy. We have shown that this Bayesian modeling approach predicted the time course and extent of CD4+ T-cell immune reconstitution after SCID transplantation.
Identifiants
pubmed: 35242727
doi: 10.3389/fped.2021.804912
pmc: PMC8885722
doi:
Types de publication
Journal Article
Langues
eng
Pagination
804912Informations de copyright
Copyright © 2022 Diana, Bouazza, Couzin, Castelle, Magnani, Magrin, Rosain, Treluyer, Picard, Moshous, Blanche, Neven and Cavazzana.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The Reviewer SP has declared a past collaboration with several of the authors DM and BN to the handling editor.
Références
Front Immunol. 2020 Feb 21;11:239
pubmed: 32153572
Blood. 2018 Oct 25;132(17):1737-1749
pubmed: 30154114
Blood. 2005 Jan 15;105(2):886-93
pubmed: 15358630
J Clin Immunol. 2018 Jan;38(1):129-143
pubmed: 29226301
Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):73-5
pubmed: 18162224
J Allergy Clin Immunol. 2017 Apr;139(4):1302-1310.e4
pubmed: 27658761
Bone Marrow Transplant. 2021 Sep;56(9):2052-2062
pubmed: 34226669
Biol Blood Marrow Transplant. 2019 Oct;25(10):2045-2053
pubmed: 31247315
Biometrics. 2020 Mar;76(1):316-325
pubmed: 31393003
Front Immunol. 2020 Aug 18;11:1988
pubmed: 33013851
Blood. 2009 Apr 23;113(17):4114-24
pubmed: 19168787
J Allergy Clin Immunol. 2021 Oct 27;:
pubmed: 34718043
Front Immunol. 2013 Nov 11;4:366
pubmed: 24273540
PLoS One. 2017 Apr 11;12(4):e0175337
pubmed: 28399164
Front Immunol. 2016 Nov 17;7:507
pubmed: 27909435
J Transl Med. 2016 Aug 02;14(1):230
pubmed: 27484705
Blood. 2014 Jan 9;123(2):281-9
pubmed: 24144642
Blood. 2016 Dec 8;128(23):2734-2741
pubmed: 27702800
Blood. 2017 Dec 21;130(25):2718-2727
pubmed: 29021228
PLoS One. 2014 Oct 14;9(10):e109832
pubmed: 25314659
Bone Marrow Transplant. 2010 Apr;45(4):613-21
pubmed: 19701252
Clin Pharmacol Ther. 2017 Aug;102(2):349-357
pubmed: 28074473
J Allergy Clin Immunol. 2014 Feb;133(2):597-9
pubmed: 24331379